INFLIXIMAB, FOLINIC ACID, IMFINZI 50 mg/mL concentrate for solution for infusion., DOCETAXEL, PLACEBO, OXALIPLATIN, FLUOROURACIL, MYCOPHENOLATE MOFETIL
D910GC00001
Phase 3 small_molecule active
Quick answer
INFLIXIMAB, FOLINIC ACID, IMFINZI 50 mg/mL concentrate for solution for infusion., DOCETAXEL, PLACEBO, OXALIPLATIN, FLUOROURACIL, MYCOPHENOLATE MOFETIL for Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition). is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active